SEATTLE, WA--(Marketwired - Apr 22, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) announced today that its wholly-owned subsidiary, The National Reference Laboratory for Breast Health Inc. (NRLBH), has been credentialed as an in-network provider for its Pharmacogenetic and Nipple Aspirate Fluid cytology laboratory procedures by Meridian Health Plan of Michigan (MHPM), which includes its commercial HMO Network as well as MHPM Medicaid Managed Care Network, Meridian Advantage Plan of Michigan (HMO SNP) Medicaid MA-PD Plan Network, MHPM Michigan MI Health Link Network and MHPM MICHILD Network.

These Meridian Health Plans of Michigan cover more than 400,000 lives, including more than 290,000 Medicaid enrollees through a contract with the Michigan Department of Community Health. Meridian Health Plan of Michigan's corporate headquarters are located in Detroit, Michigan and currently operates in 67 counties.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, commented, "Central to Atossa Genetics' mission is providing our valuable laboratory procedures to all patients who need them. Our agreement with Meridian Health Plan of Michigan allows the NRLBH to provide high quality genetic and NAF cytology services to patients who are participants in the various Meridian Health Plans of Michigan. We are pleased to be an in-network provider, and look forward to supporting the Meridian Health Plans, their patients and providers."

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to achieve its objectives and continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward-looking statement.

Contact Information:

Kyle Guse
Chief Financial Officer and General Counsel
(O) +1 800-351-3902

Investor Relations
CorProminence LLC
Scott Gordon
(O) +1 516-222-2560